CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.

TitleCREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
Publication TypeJournal Article
Year of Publication2017
AuthorsJiang Y, Ortega-Molina A, Geng H, Ying H-Y, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X, Teater M, Meydan C, Li Z, Poloway D, Wang S, Ennishi D, Scott DW, Stengel KR, Kranz JE, Holson E, Sharma S, Young JW, Chu C-S, Roeder RG, Shaknovich R, Hiebert SW, Gascoyne RD, Tam W, Elemento O, Wendel H-G, Melnick AM
JournalCancer Discov
Date Published2017 01
KeywordsAcetylation, Animals, Cell Line, Tumor, CREB-Binding Protein, Enhancer Elements, Genetic, Gene Knockout Techniques, Germinal Center, Histone Deacetylases, Histones, Humans, Lymphoma, Large B-Cell, Diffuse, Mice, Mutation, Neoplasm Transplantation, Nuclear Receptor Co-Repressor 2, Proto-Oncogene Proteins c-bcl-6, Transcription, Genetic

Somatic mutations in CREBBP occur frequently in B-cell lymphoma. Here, we show that loss of CREBBP facilitates the development of germinal center (GC)-derived lymphomas in mice. In both human and murine lymphomas, CREBBP loss-of-function resulted in focal depletion of enhancer H3K27 acetylation and aberrant transcriptional silencing of genes that regulate B-cell signaling and immune responses, including class II MHC. Mechanistically, CREBBP-regulated enhancers are counter-regulated by the BCL6 transcriptional repressor in a complex with SMRT and HDAC3, which we found to bind extensively to MHC class II loci. HDAC3 loss-of-function rescued repression of these enhancers and corresponding genes, including MHC class II, and more profoundly suppressed CREBBP-mutant lymphomas in vitro and in vivo Hence, CREBBP loss-of-function contributes to lymphomagenesis by enabling unopposed suppression of enhancers by BCL6/SMRT/HDAC3 complexes, suggesting HDAC3-targeted therapy as a precision approach for CREBBP-mutant lymphomas.

SIGNIFICANCE: Our findings establish the tumor suppressor function of CREBBP in GC lymphomas in which CREBBP mutations disable acetylation and result in unopposed deacetylation by BCL6/SMRT/HDAC3 complexes at enhancers of B-cell signaling and immune response genes. Hence, inhibition of HDAC3 can restore the enhancer histone acetylation and may serve as a targeted therapy for CREBBP-mutant lymphomas. Cancer Discov; 7(1); 38-53. ©2016 AACR.See related commentary by Höpken, p. 14This article is highlighted in the In This Issue feature, p. 1.

Alternate JournalCancer Discov
PubMed ID27733359
PubMed Central IDPMC5300005
Grant ListR01 CA178765 / CA / NCI NIH HHS / United States
T32 CA009582 / CA / NCI NIH HHS / United States
R01 CA190384 / CA / NCI NIH HHS / United States
P01 CA023766 / CA / NCI NIH HHS / United States
R01 CA183876 / CA / NCI NIH HHS / United States
P50 CA192937 / CA / NCI NIH HHS / United States
R01 CA194547 / CA / NCI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
R01 CA187109 / CA / NCI NIH HHS / United States
R01 CA164605 / CA / NCI NIH HHS / United States